

# Aims

Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include - besides the "classic" clinical specialties - pathologists, molecular biologists and oncogeneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 15<sup>th</sup> Breast Cancer Conference includes highly qualified international faculty, but will maintain its characteristics of a friendly forum where opinion leaders and attendees might exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 15<sup>th</sup> AIBCC will award the 9<sup>th</sup> International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. We also welcome the presentation of posters from participants and the best poster will be awarded during the Award Ceremony.

The Conference is addressed to medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists who will have the opportunity to interact with breast cancer leaders and exchange experiences in a friendly atmosphere.

# Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses. It won't be possible to give credits to physicians specialized in different fields.

# **Programme**

# Thursday, October 10<sup>th</sup>

8.30	Registration
9.15	Introduction to the Conference Pierfranco Conte, Gabriel N. Hortobagyi
9.30	Lecture Essential requirements for quality of care in breast cancer Laura Biganzoli
	SESSION I - PREVENTION AND SCREENING: FROM LIFE-STYLE TO MULTIGENE PANELS Chairmen: Francesca Caumo, Stefania Zovato
10.00	<b>Diet: myths and facts</b> Riccardo Caccialanza
10.20	Chemoprevention: how scientific evidence is applicable in daily practice Claudine Isaacs
10.40	The wave of multigene panels Marco Montagna
11.00	Personalized screening Francesca Caumo
11.20	Q&A
11.30	Coffee break
	SESSION II - LOCOREGIONAL TREATMENT Chairmen: Jacek Jassem, Claudine Isaacs
11.50	De-escalating surgery for breast cancer: the surgeon's point of view Viviana E. Galimberti
12.10	De-escalating surgery for breast cancer: the oncologist's point of view Gabriel N. Hortobagyi

12.30	Radiation therapy: updates Philip Poortmans
12.50	Q&A
13.00	Lunch
14.00	Multidisciplinary Tumor Board 1 Locoregional treatment Chairman: Viviana E. Galimberti Panelists: Maia Dzhugashvili, Hesham Elghazaly, Jacek Jassem, Claudine Isaacs, Philip Poortmans
	- Clinical case: margins in DCIS - Tania Saibene
	- Clinical case: BLS before/after neoadjuvant therapy Sabrina Fontana Kahler Ribeiro
	- Clinical case: partial breast irradiation - Emanuela Olmetto
	- Concluding comments - Viviana E. Galimberti
	SESSION III – LIFE AFTER BREAST CANCER Chairmen: Alessandra Andrisani, Stefania Migliuolo
15.30	<b>Gynecologic consequences</b> Marco Gambacciani
15.50	Cognitive consequences Matti Aapro
16.10	Social impact Stefania Migliuolo
16.30	Pregnancy and fertility Matteo Lambertini
16.50	Q&A
17.00	COFFEE WITH PROFESSORS - Career Development
	Clinical research in Breast Cancer: medical oncology Pierfranco Conte, Gabriel N. Hortobagyi

**Clinical research in Breast cancer: surgery and radiotherapy** Viviana E. Galimberti, Philip Poortmans Translational research in breast cancer - Mafalda Oliveira, Aleix Prat

Adjourn 18.00

Friday,	October 11 <sup>th</sup>
8.00	Poster display
	SESSION IV – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY Chairmen: Enrico Orvieto, Aleix Prat
9.00	PDL1 test in breast cancer: which, when and why? Giancarlo Pruneri
9.20	Tumor infiltrating lymphocytes in breast cancer: role in clinical practice Roberto Salgado
9.40	Clinical impact of genomics for HER2+ and TNBC Aleix Prat
10.00	Prognostic multigene assays for HR+ breast cancer: who are the patients to be tested?  Maria Vittoria Dieci
10.20	Q&A
10.40	Coffee Break
	<b>SESSION V – SYSTEMIC TREATMENTS FOR EARLY BREAST CANCER</b> Chairmen: Stephen Johnston, Gabriel N. Hortobagyi
11.00	Neoadjuvant therapy: values and pitfalls Valentina Guarneri
11.20	Enhancing chemotherapy for early TNBC: the debate around platinum and capecitabine Hope Rugo
11.40	More or less chemotherapy? Role of anthracycline in the era of personalized medicine Miguel Martin

12.20 Enhanced endocrine therapy for premenopausal patients:
OFS plus what?
Sibylle Loibl

Enhanced endocrine therapy: who needs extended endocrine therapy?

12.40 **Q&A** 

Stephen Johnston

12.00

13.00	Lunch
14.00	Multidisciplinary Tumor Board 2 Early breast cancer: challenging cases for pathologists and clinicians Chairman: Giancarlo Pruneri Panelists: Gabriel N. Hortobagyi, Sibylle Loibl, Miguel Martin, Enrico Orvieto, Aleix Prat
	- Clinical case: "rare" HER2 ISH patterns (i.e. ratio >2.0 with HER2 copies <4; ratio <2.0 with HER2 copies 4-6) - Vassilena Tsvetkova
	- Clinical case: progression during NACT - Luisa Carbognin
	<ul> <li>Clinical case: HR+/HER2-ve (1 premenopause, 1 postmenopause)</li> <li>to discuss HT+/-OFS and Extended HT - Giacomo Pelizzari</li> </ul>
	- Concluding comments - Miguel Martin
	SESSION VI – ADVANCED BREAST CANCER Chairmen: Miguel Martin, Hope Rugo
	New therapeutic algorithms
15.30	HR+ disease: what after failure of CDK4/6 inhibitors? Stephen Johnston
15.50	<b>HER2+ disease</b> Sandra Swain
16.10	<b>Biopsy of metastases and ctDNA to guide treatment</b> Gabriel N. Hortobagyi
16.30	Q&A
16.45	<b>Updates in immunotherapy for breast cancer</b> Hope Rugo
17.00	Adjourn
18.00	Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2019 and best poster award
18.15	Lecture of the Awardee
18.45	Cocktail
	The Ceremony and the cocktail will take place in Palazzo Bo, Via VIII Febbraio 2, Padua

## Saturday, October 12th

### SESSION VII – ACTIONABLE PATHWAYS AND NEW DRUGS

Chairmen: Pierfranco Conte, Sibylle Loibl

# 9.00 Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer

Chairman: Sandra Swain

Panelists: Jacek Jassem, Stephen Johnston, Philip Poortmans, Hope Rugo

- Clinical case: CDK4/6: Management of toxicity Carlo Alberto Giorgi
- Clinical case: brain disease or leptomeningeal disease Gaia Griguolo
- Clinical case: discordant phenotype Federica Miglietta
- Clinical case: visceral oligometastatic disease Giuseppe Buono
- Concluding comments Sandra Swain

## 11.00 Cancer metastasis as mechano disease Stefano Piccolo

- 11.30 Coffee break
- 11.50 **New promising drugs in development** Giuseppe Curigliano
- 12.10 NGS in metastatic breast cancer: promises and pitfalls Mafalda Oliveira
- 12.30 **Q&A**
- 13.00 Adjourn and final evaluation questionnaire

# **Directors**

#### Pier Franco Conte

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Gabriel N. Hortobagyi

Department of Breast Medical Oncology The University of Texas - MD Anderson Cancer Center Houston (USA)

# Scientific Committee

### Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear medicine University of Ainshams Cairo (EG)

#### Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Jacek Jassem

Department of Oncology and Radiotherapy Medical University of Gdansk (PL)

#### Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

#### Sibylle Loibl

German Breast Group University of Frankfurt (D)

### **Eleuterios Mamounas**

Comprehensive Breast Program MD Anderson Cancer Center Orlando Orlando (F)

#### Miguel Martin

Medical Oncology Service Hospital Universitario Gregorio Marañon Madrid (E)

### Stefania Migliuolo

Europa Donna Italia Milan (I)

#### Fedro Alessandro Peccatori

Department of Medical Oncology European Institute of Oncology (IEO) Milan (I)

#### **Philip Poortmans**

President of ECCO
Department of Radiation Oncology
Institut Curie
Paris (F)

#### **Aleix Prat**

Medical Oncology Department Hospital Clinic Barcellona (E)

# Speakers

#### Matti S. Aapro

Multidisciplinary Oncology Institute Clinique De Genolier Genolier (CH)

#### Alessandra Andrisani

Department of Women's and Children's Health University of Padua (I)

### Laura Biganzoli

Breast Unit Prato Hospital AUSL Toscana Centro Prato

#### Giuseppe Buono

Oncology Unit A.O.U. Federico II Napoli (I)

#### Riccardo Caccialanza

Dietetics and Clinical Nutrition Service IRCCS Policlinico San Matteo Pavia (I)

#### Luisa Carbognin

Division of Gynecologic Oncology, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Roma (I)

#### Francesca Caumo

Radiology Unit Istituto Oncologico Veneto IRCCS University of Padua (I)

### Giuseppe Curigliano

Department of Oncology European Institute of Oncology University of Milan (I)

#### Maria Vittoria Dieci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Maia Dzhugashvili

Department of Radiation Oncology Instituto Madrileño de Oncología (Grupo IMO) Murcia (E)

#### Sabrina Fontana Kahler Ribeiro

Unit of Molecular Senology European Institute of Oncology Milan (I)

#### Viviana E. Galimberti

Unit of Molecular Senology European Institute of Oncology Milan (I)

### Marco Gambacciani

Obstetrics & Gynecology Unit S. Chiara Hospital Pisa (I)

#### Carlo Alberto Giorgi

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Gaia Griguolo

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Claudine Isaacs

Cancer Center Georgetown University Washington (USA)

#### Matteo Lambertini

Breast Unit IRCCS AOU San Martino – IST Genova (I)

#### Federica Miglietta

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

### Marco Montagna

Hereditary Tumors Group Breast and Ovary Cancer Department of Oncological Molecular Diagnostic and Immunology Istituto Oncologico Veneto University of Padua (I)

#### Mafalda Oliveira

Medical Oncology Department; Breast Cancer Group Vall d'Hebron University Hospital; Vall d'Hebron Institute of Oncology (VHIO) Barcellona (S)

#### Emanuela Olmetto

Department of Radiation Oncology Careggi Hospital Firenze (I)

#### **Enrico Orvieto**

General Pathology and Cytopatology Unit Department of Medicine-DIMED University of Padua (I)

### Giacomo Pelizzari

Medical Oncology Oncology Center Aviano (I)

#### Stefano Piccolo

Histology and Embryology Section Department of Medical Biotechnology University of Padua (I)

#### Giancarlo Pruneri

Department of Patholgy 2 Fondazione IRCCS Istituto Nazionale dei Tumori Milano

#### Hope Rugo

UCSF Carol Franc Buck Breast Care Center Breast Oncology Clinical Trials Program San Francisco (USA)

#### Tania Saibene

Breast Surgery Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Roberto Salgado

Department of Pathology, GZA-ZNA, Antwerp, Belgium Division of Research, Peter Mac Callum Cancer Centre, Melbourne, Australia

#### Sandra Swain M.

Research Development Georgetown University Medical Center Washington (USA)

#### Vassilena Tsvetkova

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Stefania Zovato

Familial Cancer Clinic Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology Padova (I)

# Award & Fellowships & Poster Session

## **UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2019**

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. Prof. Conte and Prof. Hortobagyi will select the final winner which will be invited to present his/her study during the annual Conference.

### **POSTER SESSION**

Participants can send one or more abstracts.

The form (available on the web site: <a href="https://meettheprofessor.accmed.org">https://meettheprofessor.accmed.org</a>) should be filled out by following specific guidelines:

- Use the capitol letter for the title
- Indicate each author's affiliation (that should include institution, department and town)
- Underline the designated presenting author's name.
- Use font Times New Roman 10, single line spacing.

Abstracts will be selected by the Scientific Committee and will be shown during the poster session on October 11<sup>th</sup> from 8 am. Poster size: 70 (wide) x 100 (high).

People sending the selected abstracts will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement € 200,00 for Italian participants and € 300,00 for European and worldwide participants).

Abstracts should be sent within September 10<sup>th</sup>. A confirmation will be sent by email within September 15<sup>th</sup>.

## **FELLOWSHIPS**

Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within September 10<sup>th</sup>.

The organizing secretariat will confirm the award of the fellowship within September 15<sup>th</sup> and it will proceed with the organization of logistics.

# **Under 40**

Free admission is available for a few people "under 40".

Registration forms will be accepted on a first-come, first-served basis until spaces will be full.

The Organization Secretariat will confirm the registration by email.



# **CME**

Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (**31-265479**): **11,2 CME points**.

The credit certification is subject to:

- Professions/specializations should correspond to those which have been accredited for CME;
- 90% attendance to the meeting;
- Completion of the meeting evaluation form;
- Completion of the final questionnarie (at least 75% of correct answers).

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.

# Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

# Registration

The registration fees are:

- € **250,00** - € **150,00** for graduate students - € **150,00** for nurses They include the conference bag and all coffee breaks and lunches. They do not include Hotel accomodation, dinners and travel expenses.

To register, please send:

- registration form duly filled out (even when sponsored by a Pharmaceutical Company)
- privacy statement and consent to the use of personal data (as in the back of the form)
- payment

to Accademia Nazionale di Medicina - Galleria Ugo Bassi 2, 40121 Bologna (fax 0039 51 0569162 – e.mail: info.bologna@accmed.org), within September 25<sup>th</sup>, 2019.

Online registration is possible on the website **http://meettheprofessor.accmed.org.** 

By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat.

Incomplete registration will NOT be admitted.

The registration will be confirmed by e-mail, please put your e-mail address on the registration form.

#### **CANCELLATION**

- If the participants minimum number is not reached, Accademia Nazionale di Medicina will advise by a written communication and proceed with the total refund of the fee.
- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

# Meeting Venue

Congress Centre Villa Ottoboni Via Padre E. Ramin, 1 Padova

How to reach the meeting venue:

Radio taxi: 049 651333

The Congress Center has a large and free parking.

# With the patronage of

## **INSTITUTIONS**















## SCIENTIFIC SOCIETIES













# With the unconditional sponsorship of

**GOLD SPONSOR** 





SILVER SPONSOR



**BRONZE SPONSOR** 









**CONTRIBUTORS** 









